Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Stabilised GHRH analogue — human GHRH(1-44) amide, N-terminally acylated

Tesamorelin

An approved GHRH analogue and the only GHRH analogue in this library with a currently marketed United States approval.

Also listed as: Egrifta, TH9507, Tesamorelin acetate

Chemical identity

Compound class
Stabilised GHRH analogue — human GHRH(1-44) amide, N-terminally acylated
Sequence
trans-3-hexenoyl-GHRH(1-44)-NH2
Molecular formula
C221H366N72O67S
Molecular weight
5136 g/mol
CAS number
218949-48-5
PubChem CID
16137828
Research categories
GHRH analogues, Approved drug substances

United States regulatory status

FDA-approved drug substance

BLA 022505 (EGRIFTA)

Marketed in the United States as EGRIFTA, an approved prescription product administered subcutaneously.

  • EGRIFTA, BLA 022505, approved 10 November 2010. Active prescription product.
  • Not listed on FDA's Category 2 or withdrawn-nomination compounding tables.

Anti-doping status

Named at S2.2.4 among GHRH analogues. Prohibited at all times; non-Specified.

Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.

Evidence overview

3 records in this file

  • CLINICAL TRIAL1
  • REGULATORY2

Research areas. Anti-doping; Approved-drug Phase 3; United States approval.

Publication span. 2007–2026.

Open the evidence file

What we know

  • FDA-approved as EGRIFTA (BLA 022505, 2010). Falutz et al. 2007 (NEJM) is a primary interventional paper in the HIV-lipodystrophy programme.
  • It is the only GHRH analogue in this library with a currently marketed United States approval.
  • Also named on the WADA GHRH-analogue list — approval and sporting prohibition are different questions.

Editorial reading of the records below, labelled as Therapept analysis. How records are built

What remains uncertain

  • Orthopaedic or “performance” endpoints: 2026 sports-medicine reviews report no supporting evidence in those settings.

Sources

  1. PubChem CID 16137828
  2. Drugs@FDA — approved drug products
  3. WADA 2026 Prohibited ListEffective 1 January 2026.

Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built